An interventional study of Robotic platform monitoring system in User Experience, Usability and Acceptability, sponsored by Ernesto Losavio. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Ernesto Losavio · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Frailty is not related exclusively to age, but represents a state of increased biological and clinical vulnerability characterized by reduced functional reserve and greater susceptibility to adverse events, even in response to minor stress factors. In patients with complex conditions, such as severe acquired brain injuries, early detection and prompt treatment of clinical deterioration are essential to reduce the risk of acute readmission, complications, and in-hospital mortality. Many of these events are potentially predictable and preventable, given the presence of appropriate monitoring systems.
Advanced care models, including early warning systems, have been developed to support healthcare professionals in identifying patients at risk by detecting significant changes in physiological parameters. In recent years, technological innovations-particularly in the fields of robotics and telemedicine-have created new opportunities to enhance clinical monitoring, enabling more systematic data collection and timely clinical assessment.
Social assistive robots are emerging as promising tools in healthcare settings. These systems can support clinicians and nurses in routine monitoring activities, help reduce workload, and facilitate more efficient and personalized care. By integrating robotic assistance with digital health platforms, it may be possible to support patient monitoring and clinical workflow, particularly in high-complexity environments such as neurorehabilitation units.
This study focuses on the use of an innovative robotic telemedicine system based on the integration of the MOVER-L prototype with the ROB.IN.CARE platform, owned by Item Oxygen Srl, which purchased the platform from CO-ROBOTICS S.R.L. through the PON SI-ROBOTICS project. The system is designed to support the monitoring of patients' clinical conditions by integrating physiological and clinical data and identifying predefined signs of potential deterioration. It supports healthcare professionals by providing clinical information and automated alerts that prompt healthcare-professional review.
The study is a low-intensity, non-randomized controlled pilot feasibility interventional study conducted in a Neurorehabilitation Unit. Patients with varying levels of clinical severity, classified according to the Glasgow Coma Scale, are enrolled and allocated to one of two groups: a control group receiving standard care and an experimental group monitored using the robotic system in addition to usual care.
The primary objective of the study is to evaluate the feasibility, usability, safety, and reliability of this robotic telemedicine solution in a real clinical setting. In addition, the study assesses its acceptability among both patients and healthcare professionals. These aspects are evaluated using predefined feasibility and technical measures together with validated assessment tools, including the System Usability Scale (SUS) and the Health and Safety Executive Stress Indicator Tool (HSE). The specific role and interpretation of these measures are defined in the study protocol.
The integrated MOVER-L/ROB.IN.CARE system combines robotic assistance with the acquisition and integration of physiological and clinical data through a dedicated software architecture. The platform incorporates algorithms designed to stratify clinical risk and assess patient severity. It utilizes established clinical scoring systems, such as the Modified Early Warning Score (MEWS) for early detection of clinical deterioration, the quick Sequential Organ Failure Assessment (qSOFA) for risk assessment in patients with suspected infection, and the Kidney Disease: Improving Global Outcomes (KDIGO) criteria for the assessment of acute kidney injury.
The present pilot study is intended to characterize the feasibility of integrating the MOVER-L/ROB.IN.CARE system into routine neurorehabilitation practice, including its technical performance, usability, safety, acceptability, and integration into the clinical workflow. The findings are intended to identify implementation requirements and sources of variability and to inform the design of subsequent adequately powered studies evaluating the clinical impact of robotic monitoring.
543 studies on the registry are indexed under Personal Satisfaction; 91 are open to participants now.
This study's planned enrollment of 12 is below the median of 93 across 418 interventional studies indexed under Personal Satisfaction.
Browse Personal Satisfaction studies →Ernesto Losavio is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants allocated to the experimental group will receive standard clinical care in addition to monitoring supported by the MOVER-L robotic platform and ROB.IN.CARE software. Robot-assisted monitoring will be performed for approximately 12 hours per day for five consecutive days.
Device: Robotic platform monitoring system
Participants allocated to the control group will receive standard clinical care according to routine clinical practice, including conventional medical and nursing assessments. No robotic monitoring will be performed.
The MOVER-L robotic platform, integrated with the ROB.IN.CARE clinical decision-support software, will support patient monitoring by integrating physiological and clinical data acquired from connected medical devices, dedicated sensors, and clinical assessments. The software will use these data to calculate established clinical scores, including MEWS, qSOFA, and KDIGO, and to characterize the patient's clinical risk status. When predefined clinical thresholds are reached, the system will generate alerts prompting review by healthcare professionals. All alerts will be interpreted within the patient's clinical context, and all diagnostic and therapeutic decisions will remain under the responsibility of the healthcare team.
Also known as: robotic platform, monitoring system
Health and Safety Executive (HSE) Management Standards Indicator Tool
The Health and Safety Executive (HSE) Management Standards Indicator Tool is a 35-item questionnaire assessing psychosocial working conditions across seven domains: demands, control, managerial support, peer support, relationships, role, and change. In the present pilot study, the HSE Indicator Tool will be used to characterize the work-related organizational context of participating healthcare professionals and will not be interpreted as a measure of change attributable to the 5-day robotic intervention. The questionnaire will be administered once to participating healthcare professionals.
Time frame: Following exposure to the robotic system, at the end of the 5-day study period.
System Usability Scale (SUS)
The System Usability Scale (SUS) is a validated 10-item questionnaire used to assess perceived system usability. Each item is rated on a 5-point Likert scale. Scores are calculated according to the standard SUS scoring procedure and transformed to a total score ranging from 0 to 100, with higher scores indicating greater perceived usability. The questionnaire will be administered once to participating healthcare professionals following their exposure to the MOVER-L/ROB.IN.CARE system.
Time frame: Following exposure to the robotic system, at the end of the 5-day study period.
Oxygen Saturation
Peripheral oxygen saturation (SpO₂) measured by pulse oximetry (%).
Time frame: From enrollment to the end of the 5-day study period
Heart Rate
Heart rate measured in beats per minute (bpm).
Time frame: From enrollment to the end of the 5-day study period
Systolic Blood Pressure
Systolic blood pressure measured in millimeters of mercury (mmHg).
Time frame: From enrollment to the end of the 5-day study period
Body Temperature
Body temperature measured in degrees Celsius (°C).
Time frame: From enrollment to the end of the 5-day study period
Respiratory Rate
Respiratory rate measured in breaths per minute (breaths/min).
Time frame: From enrollment to the end of the 5-day study period
Level of Consciousness (Glasgow Coma Scale)
Level of consciousness assessed using the Glasgow Coma Scale (GCS), comprising Eye Opening, Verbal Response, and Motor Response components, with a total score ranging from 3 to 15 when all components are testable. Automated assessment is restricted to GCS $\\geq$ 12, whereas lower or non-testable states require bedside assessment by healthcare professionals.
Time frame: From enrollment to the end of the 5-day study period
Urine Output
Urine output expressed in mL/hour. Hourly measurements are obtained from the electronic urinometer and the three most recent hourly measurements are entered into ROB.IN.CARE every 3 hours.
Time frame: From enrollment to the end of the 5-day study period.
Serum Creatinine
Serum creatinine concentration measured in mg/dL and used as a component of KDIGO acute kidney injury assessment.
Time frame: At enrollment and when clinically available during the 5-day study period.
AVPU Level of Consciousness
Level of consciousness assessed using the Alert, Verbal, Pain, Unresponsive (AVPU) scale.
Time frame: From enrollment to the end of the 5-day study period.
No study locations are listed for this record.
Start is estimated for Oct 2026; primary completion for Nov 2026, 1 month later.
Of 250 non-industry interventional studies with no phase under Personal Satisfaction, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 21. This study's planned 1 month is below that.
Counting every sponsor, half of 257 studies reached it within 9 months; a quarter within 3 and three quarters within 21.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Oct 19, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ernesto Losavio